SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer

NCT07662811 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

396

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: SYHX2011
DRUG: Carboplatin
DRUG: Enlonstobart
DRUG: Nab-Paclitaxel
DRUG: Carboplatin
DRUG: Tislelizumab

Sponsor

Shanghai Chest Hospital